Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating severe peripheral amyloid protein misfolding diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, or by systemic amyloidosis.
Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.
Company Details
- Employees
- 12
- Founded
- -
- Address
- Boulevard Patience Et Beaujonc, 3/12,belgium
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.amyltx.com/
- HQ
- Liège, Walloon Region
Amyl Therapeutics Questions
Amyl Therapeutics's website is https://www.amyltx.com/
Amyl Therapeutics's LinkedIn profile is https://be.linkedin.com/company/amyl-therapeutics
Amyl Therapeutics has
12 employees.
View email and phone details for 12
employees at Amyl Therapeutics.
Amyl Therapeutics's industry is
Biotechnology Research
Amyl Therapeutics's top competitors are
Légiapark,
Exo Biologics,
Theratrame,
Exothera,
Pdc*line Pharma,
Kiomed Pharma,
Esobiotec,
Novadip Biosciences S.a.,
Hyloris Pharmaceuticals,
Eyed Pharma.
Amyl Therapeutics's categories are Biotechnology Research
Amyl Therapeutics's founding year is 2020
